Renaissance Technologies (RenTech)'s TNDM Position Overview
Renaissance Technologies (RenTech) (via Renaissance Technologies LLC) currently holds 58,227 shares of Tandem Diabetes Care, Inc. (TNDM) worth $1.12 M, representing 0.00% of the portfolio. First purchased in 2017-Q4, this long-term strategic position has been held for 31 quarters.
Based on 13F filings, Renaissance Technologies (RenTech) has maintained a strategic position in TNDM, demonstrating sustained confidence in this investment. Largest addition occurred in Q4 2018, adding 1.02 M shares. Largest reduction occurred in Q1 2019, reducing 637,900 shares.
Analysis based on 13F filings available since 2013 Q2
Renaissance Technologies (RenTech)'s Tandem Diabetes Care (TNDM) Holding Value Over Time
Track share changes against reported price movement
Quarterly Tandem Diabetes Care (TNDM) Trades by Renaissance Technologies (RenTech)
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | +58,227 | New Buy | 58,227 | $19.17 |
| Q4 2025 | -161,500 | Sold Out | 0 | $0.00 |
| Q3 2025 | -180,827 | Reduce 52.82% | 161,500 | $12.14 |
| Q2 2025 | +56,200 | Add 19.64% | 342,327 | $18.64 |
| Q1 2025 | -29,600 | Reduce 9.38% | 286,127 | $19.16 |
| Q4 2024 | +105,300 | Add 50.04% | 315,727 | $36.02 |
| Q3 2024 | -85,396 | Reduce 28.87% | 210,427 | $42.41 |
| Q2 2024 | -298,504 | Reduce 50.23% | 295,823 | $40.29 |
| Q1 2024 | +576,100 | Add 3160.70% | 594,327 | $35.41 |
| Q4 2023 | +18,227 | New Buy | 18,227 | $29.57 |
| Q4 2022 | -67,400 | Sold Out | 0 | $0.00 |
| Q3 2022 | -85,827 | Reduce 56.01% | 67,400 | $47.85 |
| Q2 2022 | +131,327 | Add 599.67% | 153,227 | $59.19 |
| Q1 2022 | -2,327 | Reduce 9.60% | 21,900 | $116.30 |
| Q4 2021 | -215,319 | Reduce 89.89% | 24,227 | $150.53 |
| Q3 2021 | +205,119 | Add 595.81% | 239,546 | $119.38 |
| Q2 2021 | -136,700 | Reduce 79.88% | 34,427 | $97.39 |
| Q1 2021 | -145,300 | Reduce 45.92% | 171,127 | $88.25 |
| Q4 2020 | -126,669 | Reduce 28.59% | 316,427 | $95.68 |
| Q3 2020 | -392,332 | Reduce 46.96% | 443,096 | $113.50 |
| Q2 2020 | +340,500 | Add 68.80% | 835,428 | $98.92 |
| Q1 2020 | -189,972 | Reduce 27.74% | 494,928 | $64.35 |
| Q4 2019 | -608,727 | Reduce 47.06% | 684,900 | $59.61 |
| Q3 2019 | +395,700 | Add 44.07% | 1.29 M | $58.98 |
| Q2 2019 | +123,500 | Add 15.95% | 897,927 | $64.52 |
| Q1 2019 | -637,900 | Reduce 45.17% | 774,427 | $63.50 |
| Q4 2018 | +1.02 M | Add 257.01% | 1.41 M | $37.97 |
| Q3 2018 | +189,230 | Add 91.70% | 395,594 | $42.84 |
| Q2 2018 | +49,137 | Add 31.25% | 206,364 | $22.02 |
| Q1 2018 | +130,377 | Add 485.58% | 157,227 | $4.96 |
| Q4 2017 | +26,850 | New Buy | 26,850 | $2.35 |
Renaissance Technologies (RenTech)'s Tandem Diabetes Care Investment FAQs
Renaissance Technologies (RenTech) first purchased Tandem Diabetes Care, Inc. (TNDM) in Q4 2017, acquiring 26,850 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies (RenTech) has held Tandem Diabetes Care, Inc. (TNDM) for 31 quarters since Q4 2017.
Renaissance Technologies (RenTech)'s largest addition to Tandem Diabetes Care, Inc. (TNDM) was in Q4 2018, adding 1,412,327 shares worth $53.63 M.
According to the latest 13F filing for Q1 2026, Renaissance Technologies (RenTech)'s firm, Renaissance Technologies LLC, owns 58,227 shares of Tandem Diabetes Care, Inc. (TNDM), valued at approximately $1.12 M.
As of the Q1 2026 filing, Tandem Diabetes Care, Inc. (TNDM) represents approximately 0.00% of Renaissance Technologies (RenTech)'s publicly disclosed stock portfolio, making it one of their key holdings.
Renaissance Technologies (RenTech)'s peak holding in Tandem Diabetes Care, Inc. (TNDM) was 1,412,327 shares, as reported at the end of Q4 2018.